Company profile: Amphista Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation targeted protein degradation therapies and the Eclipsys drug development platform, harnessing the body's natural processes to selectively remove disease-causing proteins. Solutions address a wide range of diseases, including oncology and CNS disorders, and are designed to overcome limitations of first-generation TPD with broad applicability and improved drug properties.
Products and services
- First-in-Class Cancer Therapeutics: Therapeutic-grade medicines that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins in oncology
- Next-Generation TPD Therapies: Mechanism-driven therapies engineered to overcome limitations of first-generation targeted protein degradation approaches, offering broad therapeutic applicability and improved drug properties
- Eclipsys Drug Development Platform: Platform-scale environment to develop novel protein-degrading therapeutics aimed at a wide range of diseases, including oncology and CNS disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amphista Therapeutics
EOS
HQ: Italy
Website
- Description: Provider of biopharmaceutical research and development focused on creating novel medicines for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EOS company profile →
VeriTeQ
HQ: United States
Website
- Description: Provider of animal and emergency identification solutions, with products used around the world for pet identification via patented, FDA-approved implantable microchips, and for livestock identification and tracking using visual and RFID ear tags.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VeriTeQ company profile →
Tokai Pharmaceuticals
HQ: United States
Website
- Description: Provider of cancer therapies, focused on developing and delivering treatments for patients living with cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tokai Pharmaceuticals company profile →
Biomea Fusion
HQ: United States
Website
- Description: Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomea Fusion company profile →
IsoPlexis
HQ: United States
Website
- Description: Provider of single-cell detection technology that identifies a wide range of patient immune responses at the single-cell level. Its platform assesses the safety and efficacy of therapeutics and monitors disease progression to support improved therapeutic development and inform physician decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IsoPlexis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amphista Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amphista Therapeutics
2.2 - Growth funds investing in similar companies to Amphista Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amphista Therapeutics
4.2 - Public trading comparable groups for Amphista Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →